|
|
|
Ex vivo gene therapy is a promising approach to orthopedic regenerative medicine, but the unregulated production of osteoinductive molecules has also resulted in abnormal bone formation and tumorigenesis. To address these limitations, Gersbach et al. (Gene Therapy, Vol. 13, pp. 873-882) describe a retroviral system to deliver the Runx2 osteoblastic transcription factor. Their results present a novel system for regulating osteoblastic differentiation of a clinically relevant autologous cell source, which is significant to developing controlled and effective orthopedic gene therapy strategies and studying the regulation of osteoblastic differentiation.
Correspondence Dr AJ García, Petit Institute for Bioengineering and Bioscience, 315 Ferst Drive, Room 2314, Atlanta, GA 30332-0363, USA. E-mail: andres.garcia@me.gatech.edu Abstract available online. (C) Gene Therapy. Posted by: Tressie Dalaya.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|